Health

Race to procure COVID-19 vaccine doses: Where do countries stand?

India has confirmed the maximum number of doses at 1.6 billion

 
By DTE Staff
Published: Friday 13 November 2020

‘Vaccine nationalism’ has increasingly become a buzzword — and a humungous global concern — as scientists across the world race to produce a preventive cure for the novel coronavirus disease (COVID-19). The disease has killed at least 1.29 million people as of November 13, 2020.

The richer countries are displaying rapid urgency to allow access to vaccine doses for their populations. High-income countries have booked 3.4 billion doses, upper middle-income countries 694 million doses, and lower middle-income countries more than 1.7 billion doses. The figures are from an analysis from researchers at Duke University’s Global Health Innovation Center.

The trend has an obvious downside: The poorer countries are likely to be left without any access.

The analysis could not find evidence of any direct deals made by low-income countries. This would mean that they would rely on COVAX Facility, a mechanism designed to guarantee fair and equitable access to COVID-19 vaccines worldwide.

COVAX aims to provide two billion doses by the end of 2021 to protect high-risk populations around the world. One of the long-term goals is to provide funded countries with enough doses to cover 20 per cent of their population. It is a partnership between GAVI, the World Health Organization and the Coalition for Epidemic Preparedness Innovations (CEPI). 

As of November 11, enough doses to cover 250 million people have been confirmed as purchased by COVAX, according to the study. 

Doses procured

As many as 6.4 billion doses of the yet-to-be-made COVID-19 vaccines have been confirmed globally, and another 3.2 billion doses are currently under negotiation.

India has confirmed the maximum number of doses at 1.6 billion: One billion from Novavax, 500 million from the Oxford University and 100 million from Gamaleya Research Institute.

The country has been able to negotiate large advance market commitments mainly due to its potential for manufacturing, the study said.

The European Union has procured rights to access 1.2 billion doses; and the United States, which is not a part of COVAX, has accessed right to one billion doses of the potential vaccines, enough to cover 230 per cent of its population.

Similarly, Canada has purchased enough to vaccinate its population five times over.

Source: Duke University

The study analysed several critical challenges to distribution through the team's interviews with officials in India, Ethiopia and Peru. Among these were:

  • Using childhood immunisation infrastructure to target elderly populations
  • Cold-chain capacity, especially in rural and remote locations (requirements range from standard refrigeration to standard freezer to ultercold at -800 degrees Celsius)
  • Needle supply and proper disposal of biohazard waste
  • Lack of trained providers to implement vaccines, particularly in rural areas

According to Andrea Taylor who led the analysis for the initiative:

“High-income countries are making deals with major vaccine developers who are in turn reserving the lion’s share of the world’s manufacturing capacity to meet those commitments.  We’re rapidly reaching the point where soon, even countries that have the finances to shop for vaccines will find there is no manufacturing capacity available to fill their needs. Even with new investments to build or retrofit additional facilities, there is a limit to how much global vaccine manufacturing capacity can expand in the next few years.”

Subscribe to Weekly Newsletter :
Related Stories

Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.